Hint mode is switched on Switch off
For swift navigation between sections

Replimune Group
LEI 549300AY704NEIRC4K64

PDF download

Choose all Reset all
Download Cancel
Organization name
Replimune Group, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

03/02/2026 Replimune Group: Of This Current Report On Form 8k, Including Exhibit 99.1, Shall Not Be Deemed “filed” For The Purposes Of Section 18 Of Thesecurities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference In Any Filing Under Thesecurities Act Of 1933, As Amended, Or Theexchange Act, Except As Expressly Stated By Specific Reference In Such Filing, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Financial Statements And Exhibits
12/01/2026 Replimune Group: Regulation Fd Disclosure, Financial Statements And Exhibits
02/09/2025 Replimune Group: Regulation Fddisclosure, Financial Statements And Exhibits
07/08/2025 Replimune Group: Of This Current Report On Form 8k, Including Exhibit 99.1, Shall Not Be Deemed “filed” For The Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference In Any Filing Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Expressly Stated By Specific Reference In Such Filing, Financial Statements And Exhibits
21/07/2025 Replimune Group: Of This Current Report On Form8k, Including Exhibit99.1, Shall Not Be Deemed “filed” For The Purposes Of Section18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference In Any Filing Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Expressly Stated By Specific Reference In Such Filing, Other Events, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300AY704NEIRC4K64
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001737953
  • EIN
    82-2082553
Registration is required to get access.